TMFGBudwell

George Budwell

TMFGBudwell’s Activity

Today

NL

Article

gbudwell published an article 12:24 PM

Why Shares of TransEnterix Plunged Today

TransEnterix's buyout may not be imminent.

Yesterday

NL

Article

gbudwell published an article 9:16 AM

Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January

Arena's pivot away from the lethargic anti-obesity drug market didn't help it escape the biotech bloodbath last month.

NL

Article

gbudwell published an article 8:13 AM

Here's Why Celldex Therapeutics Got Crushed in January

Celldex was a victim of the market's wrath toward clinical-stage biotechs last month.

NL

Article

gbudwell published an article 7:29 AM

3 Reasons Why Celgene Corp.'s Stock Dropped 15% in January

Celgene took a bath in January, and not just because the market was shying away from all things biotech.

Mon Feb 8

NL

Article

gbudwell published an article 9:25 PM

Here's Why Juno Therapeutics Dropped 37% in January

Juno Therapeutics kicked off 2016 by losing over a third of its value. Here's why.

NL

Article

gbudwell published an article 12:17 PM

Why Heron Therapeutics' Stock Sank Today

Shares continue to churn lower along with the bulk of the entire biotech industry.

Thu Feb 4

NL

Article

gbudwell published an article 10:39 AM

Why Shares of Osiris Therapeutics Tanked Today

A shake-up in leadership sent the stock reeling.

NL

Article

gbudwell published an article 9:15 AM

Is Gilead Sciences Finally Nearing a Bottom?

The biotech remains a great buy, despite its worrisome start to the new year.

Wed Feb 3

Rule Breakers article.

gbudwell published an update. 11:01 AM

NL

Article

gbudwell published an article 8:54 AM

2 Beaten-Down Biotech Stocks to Buy in February

Bellicum Pharmaceuticals and Geron Corp. are intriguing speculative buys after getting trounced in January.

NL

Article

gbudwell published an article 7:07 AM

Why Juno Therapeutics Dropped by 10% on Tuesday

A former star among clinical-stage biotech stocks has turned into a falling knife in 2016.

Mon Feb 1

NL

Article

gbudwell published an article 11:53 AM

Here's Why Alere's Stock Is Soaring Today

Abbott Labs adds to its medical diagnostic portfolio by buying Alere for $5.8 billion.

NL

Article

gbudwell published an article 1:28 AM

Why Did Biotech Fall Off a Cliff in January?

Biotech's decline doesn't signal the start of a bear market for the industry. Here's why.

Fri Jan 29

NL

Article

gbudwell published an article 10:43 AM

Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?

Merck's new hep C drug is a major threat to both AbbVie and Gilead Sciences. Here's why.

Tue Jan 26

NL

Article

gbudwell published an article 10:19 AM

Why Shares of Relypsa Are Climbing Today

The biopharma's shares briefly spiked today on a positive clinical update for the company's closely watched treatment for hyperkalemia.

NL

Article

gbudwell published an article 8:43 AM

Will 2016 Be BioMarin Pharmaceutical's Best Year Yet?

Despite stumbling at the start of the year, the biopharma appears primed to turn in another strong year in 2016.

Mon Jan 25

NL

Article

gbudwell published an article 11:29 AM

Why OncoMed Pharmaceuticals' Stock Crashed Today

The biotech's shares sank after independent investigators reported that the company's experimental pancreatic cancer drug appears destined to miss its study goals in an ongoing midstage trial.

NL

Article

gbudwell published an article 8:37 AM

Would a Bernie Sanders Presidency Doom Obamacare?

Bernie Sanders recently rolled out his Medicare for All proposal. A deeper look, though, suggests that his plan is far from mere extension of Obamacare.

NL

Article

gbudwell published an article 5:52 AM

If You're in Your 60s, Consider Buying These Stocks

Our Foolish contributors think Enterprise Products Partners, Nike, and Pfizer are three stocks investors in their 60s should consider adding to their portfolios right now.

Fri Jan 22

NL

Article

gbudwell published an article 3:43 AM

3 Reasons Horizon Pharma plc's Stock Could Fall

The biopharma's stock could be in for a tough year. Here's why.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 74888
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 4
Total Picks 9
Best Pick RXII (+9.56)
Worst Pick IONS (-35.48)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to TMFGBudwell’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFGBudwell’s 10 Latest Posts